<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373683</url>
  </required_header>
  <id_info>
    <org_study_id>06-14-08</org_study_id>
    <nct_id>NCT02373683</nct_id>
  </id_info>
  <brief_title>Helium-oxygen Gas Mixtures Delivered by a High Flow Nasal Cannula in Bronchiolitis</brief_title>
  <official_title>Helium-oxygen Gas Mixtures Delivered by a High Flow Nasal Cannula in Bronchiolitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Western Reserve University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective pilot study is to determine the effect of heliox delivered via a
      proprietary calibrated heated and humidified high flow nasal cannula (HFNC) system (Vapotherm
      Precision Flow Heliox) in children ages 0-24 months with severe bronchiolitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Respiratory syncytial virus associated bronchiolitis is a leading cause of global infant
      morbidity and mortality [1], yet care remains largely supportive. Several recent studies show
      that a helium-oxygen gas mixture (heliox) improves outcomes in children with moderate to
      severe bronchiolitis [2-5, 7]. Heliox is a safe, inert gas with no biological effects and
      very low density [6]. By improving laminar flow, heliox improves gas exchange in conditions
      where airway resistance is increased, such as asthma, croup and bronchiolitis [6].

      Recent data shows that infants with moderate to severe bronchiolitis have a reduced length of
      hospital stay when heliox is delivered via facemask or CPAP, as compared to heliox via nasal
      cannula [2]. Limitations to this study include the small number of patients (84/319 [26%])
      who tolerated the facemask therapy and the fact that nasal cannula heliox was delivered at
      low flows (3 LPM). Oxygen is increasingly being delivered with a heated, humidified, high
      flow nasal cannula (HFNC) system to infants with moderate to severe bronchiolitis in our
      PICU. To date, there are no definitive randomized controlled trials that show the HFNC system
      is an effective treatment in bronchiolitis. However, there are several retrospective,
      prospective and pilot interventional studies showing clinical improvement in this patient
      population treated with the HFNC system [8-11]. We hypothesize that delivering heliox via a
      heated, humidified, high flow nasal cannula will be well tolerated, safe and effective.

      Specific Aim #1: The aim of this prospective pilot study is to determine the effect of heliox
      delivered via a proprietary calibrated heated and humidified high flow nasal cannula (HFNC)
      system (Vapotherm Precision Flow Heliox) in children ages 0-24 months with severe
      bronchiolitis.

      Hypothesis #1: Clinical and physiologic markers of respiratory distress will be improved in
      patients receiving heliox via HFNC compared to standard therapy following separation from
      mechanical ventilation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory Assessment Score</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in the respiratory assessment score from baseline (within 15 minutes of extubation) to 48 hours after extubation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for reintubation</measure>
    <time_frame>During hospitalization, typically 4 days to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PICU Length of Stay</measure>
    <time_frame>During hospitalization, typically 4 days to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>During hospitalization, typically 4 days to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of treatment with supplemental oxygen</measure>
    <time_frame>During hospitalization, typically 4 days to 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bronchiolitis</condition>
  <condition>Heliox</condition>
  <condition>Pediatrics</condition>
  <arm_group>
    <arm_group_label>Vapotherm-Heliox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Care dictated by clinical team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vapotherm-Heliox</intervention_name>
    <description>Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.</description>
    <arm_group_label>Vapotherm-Heliox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 0-24 months

          -  Admission to the Pediatric Intensive Care Unit

          -  Diagnosis of bronchiolitis, with respiratory syncytial virus infection confirmed by
             laboratory testing

          -  Mechanical ventilation

        Exclusion Criteria:

          -  Inclusion in another clinical trial

          -  Significant cardiac disease

          -  Anatomically abnormal airway

          -  Neurologic disease

          -  Immunodeficiency

          -  History of chronic lung disease

          -  Craniofacial anomaly

          -  Chromosomal anomalies

          -  Known or suspected dysphagia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Rotta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainbow Babies and Children's Hospital, University Hospitals Case Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine N Slain, DO</last_name>
    <phone>216-983-0088</phone>
    <email>katherine.slain@uhhospitals.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rainbow Babies Children's Hospital, University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine N Slain, DO</last_name>
      <phone>216-983-0088</phone>
      <email>katherine.slain@uhhospitals.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1. Review.</citation>
    <PMID>20399493</PMID>
  </reference>
  <reference>
    <citation>Chowdhury MM, McKenzie SA, Pearson CC, Carr S, Pao C, Shah AR, Reus E, Eliahoo J, Gordon F, Bland H, Habibi P. Heliox therapy in bronchiolitis: phase III multicenter double-blind randomized controlled trial. Pediatrics. 2013 Apr;131(4):661-9. doi: 10.1542/peds.2012-1317. Epub 2013 Mar 18.</citation>
    <PMID>23509160</PMID>
  </reference>
  <reference>
    <citation>Martinón-Torres F, Rodríguez-Núñez A, Martinón-Sánchez JM. Heliox therapy in infants with acute bronchiolitis. Pediatrics. 2002 Jan;109(1):68-73.</citation>
    <PMID>11773543</PMID>
  </reference>
  <reference>
    <citation>Kim IK, Phrampus E, Sikes K, Pendleton J, Saville A, Corcoran T, Gracely E, Venkataraman S. Helium-oxygen therapy for infants with bronchiolitis: a randomized controlled trial. Arch Pediatr Adolesc Med. 2011 Dec;165(12):1115-22. doi: 10.1001/archpediatrics.2011.605.</citation>
    <PMID>22147778</PMID>
  </reference>
  <reference>
    <citation>Gupta VK, Cheifetz IM. Heliox administration in the pediatric intensive care unit: an evidence-based review. Pediatr Crit Care Med. 2005 Mar;6(2):204-11. Review.</citation>
    <PMID>15730610</PMID>
  </reference>
  <reference>
    <citation>Liet JM, Ducruet T, Gupta V, Cambonie G. Heliox inhalation therapy for bronchiolitis in infants. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006915. doi: 10.1002/14651858.CD006915.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD006915.</citation>
    <PMID>20393951</PMID>
  </reference>
  <reference>
    <citation>Abboud PA, Roth PJ, Skiles CL, Stolfi A, Rowin ME. Predictors of failure in infants with viral bronchiolitis treated with high-flow, high-humidity nasal cannula therapy*. Pediatr Crit Care Med. 2012 Nov;13(6):e343-9. doi: 10.1097/PCC.0b013e31825b546f.</citation>
    <PMID>22805160</PMID>
  </reference>
  <reference>
    <citation>Bressan S, Balzani M, Krauss B, Pettenazzo A, Zanconato S, Baraldi E. High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study. Eur J Pediatr. 2013 Dec;172(12):1649-56. doi: 10.1007/s00431-013-2094-4. Epub 2013 Jul 31.</citation>
    <PMID>23900520</PMID>
  </reference>
  <reference>
    <citation>Milési C, Baleine J, Matecki S, Durand S, Combes C, Novais AR, Cambonie G. Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. Intensive Care Med. 2013 Jun;39(6):1088-94. doi: 10.1007/s00134-013-2879-y. Epub 2013 Mar 14. Erratum in: Intensive Care Med. 2013 Jun;39(6):1170. Combonie, Gilles [corrected to Cambonie, Gilles].</citation>
    <PMID>23494016</PMID>
  </reference>
  <reference>
    <citation>Schibler A, Pham TM, Dunster KR, Foster K, Barlow A, Gibbons K, Hough JL. Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. Intensive Care Med. 2011 May;37(5):847-52. doi: 10.1007/s00134-011-2177-5. Epub 2011 Mar 3.</citation>
    <PMID>21369809</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>February 23, 2015</last_update_submitted>
  <last_update_submitted_qc>February 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Case Western Reserve University</investigator_affiliation>
    <investigator_full_name>Katherine Slain</investigator_full_name>
    <investigator_title>DO</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

